Sucampo files for $86.25 million IPO

Sucampo Pharmaceuticals has filed for an IPO that could raise up to $86.25 million. The Bethesda, MD-based drug developer is working on drugs based on prostones, a class of compounds derived from functional fatty acids, for gastrointestinal, respiratory, vascular and central nervous system diseases. Banc of America Securities and Deutsche Bank Securities will serve as joint book-runners and lead managers for the offering. Leerink Swann & Company will be the co-manager for the offering.

- here's the release on the IPO

PLUS: Cambridge, MA-based BioVex Group filed for a $45 million IPO. Release